FDA agrees to review Moderna’s mRNA flu vaccine following initial refusal
The FDA initially refused to review Moderna’s experimental mRNA flu vaccine due to concerns over trial design but reversed its decision days later after a high-priority meeting. Moderna proposed splitting its application by age groups full approval for adults 50-64 and accelerated approval for …
Read More